Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs

The drugs shifting to preferred status — meaning they’ll be available to consumers for under $35 a month in out-of-pocket costs — were previously on tier three or excluded altogether from the PBM’s formulary lists.